LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT)

Q: What does CUSIP 539319301 represent in this 13F holders report?

CUSIP 539319301 is the security identifier for LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share in Q2 2023?

5 institutional investors reported LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share for Q2 2023. Use the holders table for investor-level position and value details.

CUSIP: 539319301

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 2,666,933
Total 13F shares: 17,340
Share change: +17,340
Total reported value: $101,452
Price per share: $5.88
Number of holders: 5
Value change: +$101,452
Number of buys: 5

Security key

539319301

Report period

Q2 2023

Institutions

Top holders

LIXT full security history Newer quarter: Q3 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC. SEC filings LIXTE BIOTECHNOLOGY HOLDINGS, INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 539319301

Newer quarter: Q3 2023

Recent filing periods:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Glenn Krinsky	3/4/5	10%+ Owner	— class O/S missing	1,474,998	$3,702,245	—	17 Dec 2021	3/4/5
Gil Schwartzberg	3/4/5	Director, 10%+ Owner	— class O/S missing	1,176,388	$2,952,733	—	31 Dec 2021	3/4/5
EP Wealth Advisors, LLC	13F	Company	— class O/S missing	2,211	$785,836	—	31 Mar 2023	13F
Ethos Financial Group, LLC	13F	Company	— class O/S missing	248,084	$205,240	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	— class O/S missing	101,209	$84,003	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	— class O/S missing	71,054	$58,783	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	— class O/S missing	35,956	$29,843	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	— class O/S missing	32,745	$27,090	—	31 Mar 2023	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	— class O/S missing	24,901	$20,601	—	31 Mar 2023	13F
Northeast Financial Consultants Inc	13F	Company	— class O/S missing	20,000	$16,546	—	31 Mar 2023	13F
UBS Group AG	13F	Company	— class O/S missing	10,722	$8,867	—	31 Mar 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	— class O/S missing	708	$1,000	—	31 Mar 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	— class O/S missing	53	$44	—	31 Mar 2023	13F
John S. Kovach	3/4/5	President and CEO, Director	— mixed-class rows	221,100 mixed-class rows	—	—	06 Nov 2022	3/4/5
James Miser	3/4/5	Chief Medical Officer	— class O/S missing	200,000	—	—	06 Nov 2022	3/4/5
Robert N. Weingarten	3/4/5	Vice President and CFO	— class O/S missing	200,000	—	—	06 Nov 2022	3/4/5
Philip F. Palmedo	3/4/5	Director	— mixed-class rows	137,720 mixed-class rows	—	—	30 Jun 2022	3/4/5

Institutional Holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) as of Q2 2023

As of 30 Jun 2023, LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) was held by 5 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 17,340 shares. The largest 5 holders included GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, UBS Group AG, Tower Research Capital LLC (TRC), and WELLS FARGO & COMPANY/MN. This page lists 5 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q4 2025 Across Filers

Q4 2025 holders

Q2 2023 holders

Holder diff

-12

Investor	Q4 2025 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.